Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Journal of Hematology & Oncology

Lenka Zdrazilova-Dubska³  Giannoula Lakka Klement³  Beatrix Bencsikova²  Regina Demlova³  Kristina Greplova¹  Katerina Pilatova³ 

[1] Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic;Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic;Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

关键词: Inflammation;    IL-8;    Angiogenesis;    Cancer;    CTAP-III;    PF-4;    Platelet;   

Others  :  806014
DOI  :  10.1186/1756-8722-6-42

 received in 2013-05-06, accepted in 2013-06-13,  发布年份 2013

【 摘 要 】

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

【 授权许可】

   
2013 Pilatova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Klement GL, Yip TT, Cassiola F, Kukuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J: Platelets actively sequester angiogenesis regulators. Blood 2009, 130:2835-2842.
• [2]Von Hundelshausen P, Petersen F, Brandt E: Platelet-derived chemokines in vascular biology. Thromb Haemost 2007, 97:704-713.
• [3]Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM: CXC chemokines in angiogenesis. J Leukoc Biol 2000, 68:1-8.
• [4]Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter RM: Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen 1997, 5:310-322.
• [5]Strieter RM, Polverini PJ, Kunkel SL: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-27357.
• [6]Deuel TF, Keim PS, Farmer M, Heinrikson RL: Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977, 74:2256-2258.
• [7]Tunnaclife A, Majumdar S, Yan B, Poncz M: Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood 1992, 79:2896-2900.
• [8]Ryo R, Nakeff A, Huang SS, Ginsberg M, Deuel TF: New synthesis of a platelet-specific protein: platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system. J Cell Biol 1983, 96:515-520.
• [9]Barber AJ, Käser-Glanzmann R, Jakábová M, Luscher EF: Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochem Biophys Acta 1972, 286:312-329.
• [10]Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, Folkman J: Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010, 85:487-493.
• [11]Zucker B, Katz R: Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991, 198:693-702.
• [12]Kaper B, Petersen F: Molecular pathways of platelet factor 4/CXCL4 signaling. Eur J Cell Biol 2011, 90:521-526.
• [13]Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA: Studies of human plate alpha-granule release in vivo. Blood 1981, 58:607-618.
• [14]Gerotziafas GT, Elalamy I, Lecrubier C, Lebrazi J, Mirshahi M, Potevin F, Lecompte T, Samama MM: The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 2001, 12:511-520.
• [15]Piepkorn MW: Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites. Biochem J 1981, 196:649-651.
• [16]Dumenco LL, Everson B, Culp LA, Ratnoff OD: Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med 1988, 112:394-400.
• [17]Yang L, Rezaie AR: Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb Haemost 2007, 97:899-906.
• [18]Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR: Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003, 102:146-151.
• [19]Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP: Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Int J Cell Cloning 1990, 8:253-259.
• [20]Han ZC, Sensébe L, Abgrall JF, Brière J: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 1990, 75:1234-1239.
• [21]Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M: Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 2007, 110:1153-1160.
• [22]Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M: Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood 2009, 114:2290-2298.
• [23]Lambert MP, Xiao L, Nguyen Y, Kowalska MA, Poncz M: The role of platelet factor 4 in radiation-induced thrombocytopenia. Int J Radiat Oncol Biol Phys 2011, 80:1533-1540.
• [24]Lecomte-Raclet L, Alemany M, Sequeira-Le Grand A, Amiral J, Quentin G, Vissac AM, Caen JP, Han ZC: New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Blood 1998, 91:2772-2780.
• [25]Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A: Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood 2003, 101:4687-4694.
• [26]Castor CW, Miller JW, Walz DA: Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Cell Biol 1983, 80:765-769.
• [27]El-Gedaily A, Schoedon G, Schneemann M, Schaffner A: Constitutive and regulated expression of platelet basic protein in human monocytes. J Leukoc Biol 2004, 75:495-503.
• [28]Lida N, Haisa M, Igarashi A, Pencev D, Grotendorst GR: Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. FASEB J 1996, 10:1336-1345.
• [29]Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I: Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol 2000, 111:1180-1189.
• [30]Resmi KR, Krishnan LK: Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation. Thromb Res 2002, 106:229-236.
• [31]Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E: Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 2006, 107:2234-2242.
• [32]Walz A, Baggioloni M: Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990, 171:449-454.
• [33]Walz A, Dewald B, von Tscharner V, Baggiolini M: Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 1989, 170:1745-1750.
• [34]Castor CW, Ritchie JC, Williams CH Jr, Scott ME, Whitney SL, Myers SL, Sloan TB, Anderson BE: Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Arthritis Rheum 1979, 22:260-272.
• [35]Ragsdale CG, Castor CW, Roberts DJ, Swartz KH: Connective tissue activating peptide III. Induction of synthesis and secretion of plasminogen activator by synovial fibroblasts. Arthritis Rheum 1984, 27:663-667.
• [36]Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD: The beta-thromboglobulins and platelet factor 4: blood platelet derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000, 67:471-478.
• [37]Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN: Structure and bioactivity of recombinant human CTAP-III and NAP-2. J Protein Chem 1997, 16:37-49.
• [38]Tai PK, Liao JF, Hossler PA, Castor CW, Carter-Su C: Regulation of glucose transporters by connective tissue activating peptide-III isoforms. J Biol Chem 1992, 267:19579-19586.
• [39]Stoeckelhuber M, Dobner P, Baumgärtner P, Ehlert J, Brandt E, Mentele R, Adam D, Engelmann B: Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III. J Biol Chem 2000, 275:37365-37372.
• [40]Hoogewerf AJ, Leone JW, Reardon IM, Howe WJ, Asa D, Heinrikson RL, Ledbetter SR: CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heaparan sulfate-degrading enzymes. J Biol Chem 1995, 7:3268-3277.
• [41]Pandya NM, Dhalla NS, Santani DD: Angiogenesis—a new target for future therapy. Vascul Pharmacol 2006, 44:265-274.
• [42]Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61:46-52.
• [43]Karpatkin S, Ambrogio C, Pearlstein E: The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res 1988, 283:585-606.
• [44]Pinedo HM, Verheul HM, D’Amato RJ, Folkman J: Involvement of platelets in tumour angiogenesis? Lancet 1998, 352:1775-1777.
• [45]Gay LJ, Felding-Habermann B: Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011, 11:123-134.
• [46]Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL: Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate α-granules and differentially released. Blood 2008, 111:1227-1233.
• [47]Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A: Platelet factor-4 modulates fibroblast growth factor 2 (FGF2) activity and inhibits FGF2 dimerization. Blood 1998, 91:3289-3299.
• [48]Gengrinowitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995, 270:15059-15065.
• [49]Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH: Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005, 280:4948-4958.
• [50]Jones SA, Dewald B, Clark-Lewis I, Baggiolini M: Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J Biol Chem 1997, 272:16166-16169.
• [51]Ehlert JE, Ludwig A, Grimm GA, Lindner B, Flad HD, Brandt E: Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood 2000, 96:2965-2972.
• [52]Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhances endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
• [53]Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA: Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg 2008, 196:690-696.
• [54]Castor CW, Whitney SL: Connective tissue activation. XIII. Stimulation of sulfated glycosaminoglycans synthesis in human connective tissue cells by peptide mediators from lymphocytes and platelets. J Lab Clin Med 1978, 91:811-821.
• [55]Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C: Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007, 100:590-597.
• [56]Grupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 1994, 127:1121-1127.
• [57]Yang L, Du J, Hou J, Jiang H, Zou J: Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer 2011, 11:s261. BioMed Central Full Text
• [58]Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A: Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999, 94:984-993.
• [59]Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
• [60]Chadderton NS, Stringer SE: Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol 2003, 35:1052-1055.
• [61]Lozano RM, Redondo-Horcajo M, Jiménez MÁ, Zilberberg L, Cuevas P, Bikfalvi A, Rico M, Giménez-Gallego G: Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic aktivity. J Biol Chem 2001, 276:35723-35734.
• [62]Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537-1549.
• [63]Struyf S, Sologni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J: Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011, 117:480-488.
• [64]Woller G, Brandt E, Mittelstädt J, Rybakowski C, Petersen F: Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol 2008, 83:936-945.
• [65]Vandercappellen J, Van Damme J, Struyf S: The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 2011, 22:1-18.
• [66]Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990, 82:848-853.
• [67]Kolber DL, Knisely TL, Malone TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 15:304-309.
• [68]Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997, 3:437-442.
• [69]Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K: Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res 2005, 25:847-852.
• [70]Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A: Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008, 27:31-40.
• [71]Petersen F, Bock LA, Flad HD, Brandt E: Chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998, 161:4347-4355.
• [72]Petersen F, Bock L, Flad HD, Brandt E: Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood 1999, 94:4020-4028.
• [73]Han ZC, Lu M, Li J, Defard M, Boval B, Schlegel N, Caen JP: Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 1997, 89:2328-2335.
• [74]Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M: Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA 1993, 90:3574-3577.
• [75]von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE: Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005, 105:924-930.
• [76]Pervushina O, Scheuerer B, Reiling N, Behnke L, Schröder JM, Kasper B, Brandt E: Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 2004, 173:2060-2067.
• [77]Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E: The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000, 95:1158-1166.
• [78]Fricke I, Mitchell D, Petersen F, Böhle A, Bulfone-Paus S, Brandau S: Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigenpresenting cells. FASEB J 2004, 18:1588-1590.
• [79]Hayashi N, Chihara J, Kobayashi Y, Kakazu T, Kurachi D, Yamamoto T, Nakajima S: Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int Arch Allergy Immunol 1994, 104(Suppl 1):57-59.
• [80]Brindley LL, Sweet JM, Goetzl EJ: Stimulation of histamine release from human basophils by human platelet factor 4. J Clin Incest 1983, 72:1218-1223.
• [81]Marti F, Bertran E, Llucià M, Villén E, Peiró M, Garcia J, Rueda F: Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol 2002, 72:590-597.
• [82]Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F: Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002, 169:770-777.
• [83]Powell JA Jr, Mousa SA: Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. J Cell Biochem 2007, 102:412-420.
• [84]Osselaer NV, Damme JV, Rampart M, Herman AG: Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Am J Pathol 1991, 13:23-27.
• [85]Malkowski MG, Lazar JB, Johnson PH, Edwards BF: The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol 1997, 226:367-380.
• [86]Belman N, Bonnem EM, Harvey HA, Lipton A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs 1996, 14:387-389.
• [87]Kahn J, Ruiz R, Kerschmann R, Berger T, Ma R, Coleman R, Alford BL: A phase 1/2 study of recombinant plateler factor 4 (rPF4) in patients with AIDS related Kaposi’s sarcoma (KS) [abstract]. Proc Am Soc Clin Oncol 1993, 12:s50.
• [88]Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E: Phase I/II study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi‘s sarcoma (AIDS-KS) [abstract]. Proc Am Soc Clin Oncol 1995, 14:s288.
• [89]Hersh EM, Wiggins CE, Crook LI, Bonem EM: Phase I study of recombinant platelet factor 4 (rPF4) in patients with metastatic melanoma and renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1995, 14:s488.
• [90]Dinapoli RP, Buckner JC, Rydberg CH, Mullan BP, Davis DH: Phase I-II study of localized injection of recombinant platelet factor 4 (rPF4) in patients (pts) with recurrent high-grade glioma [abstract]. Proc Am Soc Clin Oncol 1995.
• [91]Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE Jr, Folkman J, Klement GL: Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008, 111:1201-1207.
• [92]Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D‘Amato RJ, Klement GL, Folkman J: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15:265-273.
• [93]Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S: Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009, 27:2787-2792.
• [94]Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM: Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Am J Transl Res 2011, 3:226-233.
• [95]Grisaru D, Vlodavsky I, Prus D, Levavi H, Lessing JB, Eldor A, Friedmann Y: Connective tissue activating peptide III expression disappears progressively with increased dysplasia in human cervical epithelium. Gynecol Oncol 2000, 79:23-27.